col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


209 Results       Page 1

 [1] 
Springer-Verlag: Infectious Diseases and Therapy
  original article Date Title Authors   All Authors
1 [GO] 2025―Jan―21 Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2 Marta Colaneri, Marta Canuti, Ginevra Torrigiani, Lucia Dall’Olio, Chiara Bobbio, Sante L. Baldi, et al. (+14)
2 [GO] 2025―Jan―07 Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period Samah Hayek, Joseph Levy, Galit Shaham, Noa Dagan, Danielle Serby, Hadar Duskin-Bitan, et al. (+10)
3 [GO] 2024―Dec―30 Foreword: Prevention of COVID-19, Influenza, and Respiratory Syncytial Virus in At-Risk Populations Stefan Gravenstein
4 [GO] 2024―Dec―30 The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review Roberto Debbag, Deborah Rudin, Francesca Ceddia, John Watkins
5 [GO] 2024―Dec―30 A Narrative Review of Key Risk Factors for Severe Illness Following SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Infection Angela Branche, Mayur Ramesh, Beverly Francis
6 [GO] 2024―Dec―30 Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative Review William P. Hanage, William Schaffner
7 [GO] 2024―Dec―26 SARS-CoV-2 SPIKE Antibody Levels can Indicate Immuno-Resilience to Re-infection: a Real-World Study Yue Jin, Fei Yang, Christopher M. Rank, Stanley Letovsky, Peter Ramge, Simon Jochum
8 [GO] 2024―Dec―21 Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States Amanda Wilson, Neloufar Rahai, Ekkehard Beck, Elisha Beebe, Brian Conroy, Daina Esposito, et al. (+13)
9 [GO] 2024―Dec―09 Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study Hovav Azuly, Tali Shafat, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, et al. (+30)
10 [GO] 2024―Dec―08 A Retrospective Claims Data Analysis on the Burden of COVID-19-Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany Timotheus Stremel, Svitlana Schnaidt, Nicole Bihrer, Emma Fröling, Christian Jacob, Agnes Kisser
11 [GO] 2024―Nov―07 Global Epidemiology of Meningococcal Disease-Causing Serogroups Before and After the COVID-19 Pandemic: A Narrative Review Steven Shen, Jamie Findlow, Paula Peyrani
12 [GO] 2024―Oct―12 Respiratory Syncytial Virus Risk Profile in Hospitalized Infants and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022 Mariana Haeberer, Martin Mengel, Rong Fan, Marina Toquero-Asensio, Alejandro Martin-Toribio, Qing Liu, et al. (+10)
13 [GO] 2024―Oct―10 Bridging the Gap: Delphi Consensus Statements for SARS-CoV-2 Vaccination in Immunocompromised Patients Hersh D. Ravkin, Lior Nesher
14 [GO] 2024―Oct―10 COVID-19 Vaccination Recommendations for Immunocompromised Patient Populations: Delphi Panel and Consensus Statement Generation in the United States Kira Zhi Hua Lai, Stuart Greenstein, Rajesh Govindasamy, Jaya Paranilam, Joseph Brown, Samantha Kimball-Carroll
15 [GO] 2024―Oct―09 Delphi Panel Consensus Statement Generation: COVID-19 Vaccination Recommendations for Immunocompromised Populations in the European Union Jaya Paranilam, Francesco Arcioni, Antonio Franco, Kira Zhi Hua Lai, Joseph Brown, Samantha Kimball-Carroll
16 [GO] 2024―Oct―07 Modeling the Impact of Ensitrelvir on SARS-CoV-2 Dynamics and Its Application for Assessment of Transmission Mitigation of Patients with COVID-19 Daichi Yamaguchi, Masaya M. Saito, Ayano Hata, Ryosuke Shimizu, Shogo Miyazawa, Takamichi Baba, et al. (+2)
17 [GO] 2024―Oct―01 Response to the Letter to the Editor Regarding “Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study” Marta Canuti, Federico Fassio, Camilla Genovese, Andrea Giacomelli, Anna Lisa Ridolfo, Erika Asperges, et al. (+10)
18 [GO] 2024―Oct―01 Letter to the Editor Regarding “Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study” Jiahua Zhang, Xinjie Wang
19 [GO] 2024―Sep―27 Letter to the Editor regarding Response to “Letter to Editor: “Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19” Takahiro Takazono, Satoki Fujita, Takuji Komeda, Shogo Miyazawa, Yuki Yoshida, Yoshitake Kitanishi, et al. (+7)
20 [GO] 2024―Sep―24 Acute Cerebellitis Following COVID-19: Alarming Clinical Presentation Challenged by Normal Paraclinical Findings Samantha Poloni, Abdoulaye Hamani, Valentine Kassis, Pauline Escoffier, Beate Hagenkotter, Vincent Gendrin, et al. (+2)
21 [GO] 2024―Sep―24 Letter to the Editor: “Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19” Hideharu Hagiya
22 [GO] 2024―Sep―19 A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults” Mihaela Georgieva, Tianyu Sun, Ekkehard Beck
23 [GO] 2024―Sep―19 Letter to the Editor Regarding: “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults” Hinpetch Daungsupawong, Viroj Wiwanitkit
24 [GO] 2024―Sep―10 Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis Mitsuhiro Nagano, Kosuke Tanabe, Kazumasa Kamei, Sooyeol Lim, Honoka Nakamura, Shuhei Ito
25 [GO] 2024―Sep―04 Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19 Dipak R. Patel, Lisa Macpherson, Martin Bohm, Himanshu Upadhyaya, Carmen Deveau, Ajay Nirula, et al. (+3)
26 [GO] 2024―Aug―24 A Response to: A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework’ Ekkehard Beck, Mary T. Bausch-Jurken, Nicolas Van de Velde, Xuan Wang, Mia Malmenäs
27 [GO] 2024―Aug―24 A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-analysis Using the GRADE Framework’ Hannah R. Volkman, Jennifer L. Nguyen, Luis Jodar, John M. McLaughlin
28 [GO] 2024―Aug―24 Correction to: Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework Sushma Kavikondala, Katrin Haeussler, Xuan Wang, Mary T. Bausch-Jurken, Maria Nassim, Nitendra Kumar Mishra, et al. (+5)
29 [GO] 2024―Aug―13 Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
30 [GO] 2024―Aug―11 A Practical Approach to Tailor the Term Long COVID for Diagnostics, Therapy and Epidemiological Research for Improved Long COVID Patient Care Kathryn Hoffmann, Michael Stingl, Liam O’Mahony, Eva Untersmayr
31 [GO] 2024―Jul―21 RSV Risk Profile in Hospitalized Adults and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022 Mariana Haeberer, Martin Mengel, Rong Fan, Marina Toquero-Asensio, Alejandro Martin-Toribio, Qing Liu, et al. (+11)
32 [GO] 2024―Jul―03 Patient-Reported Outcomes in COVID-19 Treatment with Monoclonal Antibodies Reveal Benefits in Return to Usual Activities Diana Rofail, Mohamed Hussein, Ulrike Naumann, Anna J. Podolanczuk, Thomas Norton, Shazia Ali, et al. (+4)
33 [GO] 2024―Jun―28 Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19 Takahiro Takazono, Satoki Fujita, Takuji Komeda, Shogo Miyazawa, Yuki Yoshida, Yoshitake Kitanishi, et al. (+7)
34 [GO] 2024―Jun―25 Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults Tianyu Sun, Linwei Li, Katherine E. Mues, Mihaela V. Georgieva, Brenna Kirk, James A. Mansi, et al. (+2)
35 [GO] 2024―Jun―23 Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults Kate Penrose, Avantika Srivastava, Yanhan Shen, McKaylee M. Robertson, Sarah G. Kulkarni, Kristen E. Allen, et al. (+4)
36 [GO] 2024―Jun―14 Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies Chris Wynne, Abundio Balgos, Jingxin Li, Paul Hamilton, Louie Tirador, Anjuli May Jaen, et al. (+13)
37 [GO] 2024―Jun―13 Cross-Sectional Survey of Factors Contributing to COVID-19 Testing Hesitancy Among US Adults at Risk of Severe Outcomes from COVID-19 Annlouise R. Assaf, Gurinder S. Sidhu, Apurv Soni, Joseph C. Cappelleri, Florin Draica, Carly Herbert, et al. (+13)
38 [GO] 2024―Jun―03 Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir Francesca Bai, Tomaso Beringheli, Virginia Vitaletti, Andrea Santoro, Francesco Molà, Alessandro Copes, et al. (+18)
39 [GO] 2024―May―24 Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir Genoveva Cuesta, Judit Cacho, David Cucchiari, Sabina Herrera, Abiu Sempere, Tabassum Akter, et al. (+7)
40 [GO] 2024―May―21 A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19 Wang-Da Liu, Po-Hao Feng, Chien-Yu Cheng, Chun-Liang Chou, Chih-Hsin Lee, Min-Chi Lu, et al. (+14)
41 [GO] 2024―May―14 Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review Julia Richmond DiBello, Valerie T. Raziano, Xinyue Liu, Amy Puenpatom, Kathryn Peebles, Nazleen F. Khan, Deanna D. Hill
42 [GO] 2024―May―10 Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups Samah Hayek, Joseph Levy, Galit Shaham, Noa Dagan, Danielle Serby, Hadar Duskin-Bitan, et al. (+9)
43 [GO] 2024―May―04 Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials Myron J. Levin, Andrew Ustianowski, Stephane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, et al. (+5)
44 [GO] 2024―Apr―25 Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial Julie M. Strizki, Jay A. Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Jiejun Du, et al. (+4)
45 [GO] 2024―Apr―25 Modelling COVID-19 Vaccination in the UK: Impact of the Autumn 2022 and Spring 2023 Booster Campaigns Diana Mendes, Sheeja Machira Krishnan, Esmé O’Brien, Thomas Padgett, Cale Harrison, W. David Strain, et al. (+6)
46 [GO] 2024―Apr―21 Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study Marta Colaneri, Camilla Genovese, Federico Fassio, Marta Canuti, Andrea Giacomelli, Anna Lisa Ridolfo, et al. (+10)
47 [GO] 2024―Apr―12 Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study Soyoon Hwang, Nan Young Lee, Eunkyung Nam, Yu Kyung Kim, Shin-Woo Kim, Hyun-Ha Chang, et al. (+7)
48 [GO] 2024―Mar―18 Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework Sushma Kavikondala, Katrin Haeussler, Xuan Wang, Mary T. Bausch-Jurken, Maria Nassim, Nitendra Kumar Mishra, et al. (+5)
49 [GO] 2024―Mar―18 Evaluating the Demand for Nucleic Acid Testing in Different Scenarios of COVID-19 Transmission: A Simulation Study Yu-Yuan Wang, Wei-Wen Zhang, Ze-xi Lu, Jia-lin Sun, Ming-xia Jing
50 [GO] 2024―Mar―15 K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact Carolina Garcia-Vidal, Christian Teijón-Lumbreras, Tommaso Francesco Aiello, Mariana Chumbita, Rosario Menendez, Aina Mateu-Subirà, et al. (+12)
51 [GO] 2024―Mar―10 Longitudinal Molecular and Serological Evidence of SARS-CoV-2 Infections and Vaccination Status: Community-Based Surveillance Study (CONTACT) Olga Sánchez-Soliño, Ryan D. Kilpatrick, Christopher Johnson, Yixin Fang, Yizhou Ye, Negar Niki Alami, et al. (+4)
52 [GO] 2024―Mar―09 Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
53 [GO] 2024―Mar―08 Living During COVID-19 While Immunocompromised: A Patient and Physician Perspective from France Elise Foudrat, Sophie Caillard
54 [GO] 2024―Mar―05 The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review Raunak Parikh, Mitra Yousefi, Desmond Curran, Robyn Widenmaier
55 [GO] 2024―Feb―25 Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Douglas Arbetter, Seth Seegobin, et al. (+5)
56 [GO] 2024―Jan―30 Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial Russell M. Nichols, Lisa Macpherson, Dipak R. Patel, Wendy W. Yeh, Amanda Peppercorn
57 [GO] 2024―Jan―17 Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan Shohei Shinozaki, Asuka Watanabe, Masahiro Kimata, Makoto Miyazaki, Shinichiroh Maekawa
58 [GO] 2024―Jan―13 Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System Haley J. Appaneal, Kerry L. LaPlante, Vrishali V. Lopes, Catherine Martin, Laura Puzniak, Timothy L. Wiemken, et al. (+3)
59 [GO] 2024―Jan―09 Remdesivir for the Treatment of COVID-19: A Narrative Review Patrick O. Godwin, Bryan Polsonetti, Michael F. Caron, Thomas F. Oppelt
60 [GO] 2023―Dec―16 Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies Chris Wynne, Abundio Balgos, Jingxin Li, Paul Hamilton, Louie Tirador, Anjuli May Jaen, et al. (+13)
61 [GO] 2023―Dec―01 Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18-60 Years: a Single-Center, Open-Label Trial Siyue Jia, Jinlong Zhang, Xue Wang, Zhe Zhang, Busen Wang, Jun Zhang, et al. (+7)
62 [GO] 2023―Nov―23 Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial Julie M. Strizki, Jay A. Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Jiejun Du, et al. (+4)
63 [GO] 2023―Nov―02 Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial) Gustavo H. Kijak, Bahar Ahani, Douglas Arbetter, Fernando Chuecos, Vancheswaran Gopalakrishnan, Jagadish Beloor, et al. (+10)
64 [GO] 2023―Oct―13 Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea Ji Yeon Lee, Seon Hee Bu, EunHyang Song, Seongcheol Cho, Sungbong Yu, Jungok Kim, et al. (+11)
65 [GO] 2023―Oct―06 Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study Emiel Leegwater, Lisa Dol, Menno R. Benard, Eveline E. Roelofsen, Nathalie M. Delfos, Machteld van der Feltz, et al. (+14)
66 [GO] 2023―Oct―05 Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study Lorenzo Piemonti, Giovanni Landoni, Antonio Voza, Massimo Puoti, Ivan Gentile, Nicola Coppola, et al. (+28)
67 [GO] 2023―Sep―26 Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Kenneth Kim, Douglas Arbetter, et al. (+9)
68 [GO] 2023―Sep―13 Clusters of SARS-CoV-2 Infection Across Six Schools for Students with Intellectual and Developmental Disabilities Michael Gemmell, Tyler Walsh, Michael Sherby, Adwoa Imbeah, Kelly Bono, Megan Baldenweck, et al. (+2)
69 [GO] 2023―Jul―24 Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study Qinqin Zhao, Bei Zheng, Bing Han, Pinpin Feng, Zhongni Xia, Hong Jiang, et al. (+12)
70 [GO] 2023―Jun―17 Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial Himanshu P. Upadhyaya, Jenny Y. Chien, Amanda J. Long, Martin S. Bohm, Nicole L. Kallewaard, Lisa F. Macpherson, et al. (+48)
71 [GO] 2023―May―24 Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources Lianne Barnieh, Rachel Beckerman, Sushanth Jeyakumar, Alice Hsiao, James Jarrett, Robert L. Gottlieb
72 [GO] 2023―May―17 Dynamic NLR and PLR in Predicting COVID-19 Severity: A Retrospective Cohort Study Erika Asperges, Giuseppe Albi, Valentina Zuccaro, Margherita Sambo, Teresa C. Pieri, Matteo Calia, et al. (+8)
73 [GO] 2023―Apr―25 Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia Júlia Spinardi, Ana Carolina Dantas, Carolina Carballo, Karan Thakkar, Nadine Al Akoury, Moe Hein Kyaw, et al. (+3)
74 [GO] 2023―Apr―25 Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults Pete Schmidt, Jean Gong, Kristin Narayan, Deepali Gupta, Frank Engler, Yong Li, et al. (+2)
75 [GO] 2023―Mar―26 Diagnostic Accuracy of a Rapid SARS-CoV-2 Antigen Test Among People Experiencing Homelessness: A Prospective Cohort and Implementation Study Pasquale De Nardo, Maela Tebon, Alessia Savoldi, Nicola Soriolo, Elisa Danese, Denise Peserico, et al. (+9)
76 [GO] 2023―Mar―23 Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan Masahiro Kimata, Asuka Watanabe, Yukiko Yanagida, Daisuke Kinoshita, Shinichiroh Maekawa
77 [GO] 2023―Mar―22 The Significance of Epidemic Plasmids in the Success of Multidrug-Resistant Drug Pandemic Extraintestinal Pathogenic Escherichia coli Johann D. D. Pitout, Liang Chen
78 [GO] 2023―Mar―08 A Letter to the Editor Regarding ‘Identifying Gaps in the Corticosteroid Treatment of COVID-19: We Need More Studies’ Fatma Yildirim, İrem Karaman, Aşkın Güneş
79 [GO] 2023―Feb―22 Systematic Review on the Correlation Between SARS-CoV-2 Real-Time PCR Cycle Threshold Values and Epidemiological Trends Ester Sala, Isheeta S. Shah, Davide Manissero, Marti Juanola-Falgarona, Anne-Marie Quirke, Sonia N. Rao
80 [GO] 2023―Feb―17 Monoclonal Antibodies in Hospitalised Patients with COVID-19: The Role of SARS-COV-2 Serostatus in an Evolving Pandemic François Raffi, Robert L. Gottlieb
81 [GO] 2023―Feb―16 Correction to: Efficacy of Bacillus Calmette-Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial Sanjeev Sinha, Anuj Ajayababu, Himanshu Thukral, Sushil Gupta, Subhasish Kamal Guha, Ayan Basu, et al. (+21)
82 [GO] 2023―Jan―25 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults Guiling Chen, Nan Li, Xiahong Dai, Shiyan Tu, Zhenwei Shen, Kaiqi Wu, et al. (+7)
83 [GO] 2023―Jan―25 Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients Chengzhao Weng, Rongcheng Xie, Guanjie Han, Ya Yuan, Shiqin Li, Chao Wang, et al. (+3)
84 [GO] 2023―Jan―12 COVID-19 in Latin America: A Snapshot in Time and the Road Ahead Jorge LaRotta, Omar Escobar, María L. Ávila-Aguero, Juan Pablo Torres, Rodrigo Sini de Almeida, Graciela del Carmen Morales, Amit Srivastava
85 [GO] 2023―Jan―11 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA Mindy M. Cheng, Carolina Reyes, Sacha Satram, Helen Birch, Daniel C. Gibbons, Myriam Drysdale, et al. (+7)
86 [GO] 2023―Jan―09 Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review Nick Pooley, Salim S. Abdool Karim, Behazine Combadière, Eng Eong Ooi, Rebecca C. Harris, Clotilde El Guerche Seblain, et al. (+2)
87 [GO] 2023―Jan―05 The Association Between Alveolar-Arterial Oxygen Tension Difference and the Severity of COVID-19 in Patients Canbin Xie, Jiayi Deng, Fanglin Li, Chenfang Wu, Min Xu, Bo Yu, et al. (+4)
88 [GO] 2023―Jan―04 Comparison of the Distribution and Changes in the Antibiotic Resistance of Clinical Bacterial Isolates from the Lower Respiratory Tract of Children in Shenzhen Before the Epidemic, During the Epidemic, and During the Period of Normalized Prevention and Control of COVID-19 Qing Meng, Wujiao Li, Hanfang Jiang, Huimin Yan, Heping Wang, Binjun Ye, et al. (+2)
89 [GO] 2022―Dec―15 Safety Profiles of mRNA COVID-19 Vaccines Using World Health Organization Global Scale Database (VigiBase): A Latent Class Analysis Min-Taek Lee, Wonbin Choi, Seung-Hun You, Sewon Park, Jeong-Yeon Kim, Dal Ri Nam, et al. (+2)
90 [GO] 2022―Dec―15 Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group Tomás José González-López, Abelardo Bárez, Angel Bernardo-Gutiérrez, Silvia Bernat, Mariana Canaro-Hirnyk, Laura Entrena-Ureña, et al. (+6)
91 [GO] 2022―Dec―10 Characteristics and Outcomes by Ceiling of Care of Subjects Hospitalized with COVID-19 During Four Waves of the Pandemic in a Metropolitan Area: A Multicenter Cohort Study Natàlia Pallarès, Cristian Tebé, Gabriela Abelenda-Alonso, Alexander Rombauts, Isabel Oriol, Antonella F. Simonetti, et al. (+29)
92 [GO] 2022―Nov―28 Clinical Utility of Circulating Pentraxin 3 as a Prognostic Biomarker in Coronavirus Disease 2019: A Systematic Review and Meta-analysis Yani Ke, Kaihan Wu, Chenglu Shen, Yuqing Zhu, Chuchu Xu, Qiushuang Li, et al. (+2)
93 [GO] 2022―Nov―28 Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience Giusy Tiseo, Chiara Barbieri, Valentina Galfo, Sara Occhineri, Tommaso Matucci, Francesco Almerigogna, et al. (+20)
94 [GO] 2022―Nov―23 Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia Shun Ito, Masahiro Banno, Yuji Okazaki
95 [GO] 2022―Nov―23 Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia” Flavio Mantelli
96 [GO] 2022―Nov―15 Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19 Imke Kirste, Sayuri Hortsch, Veit Peter Grunert, Holly Legault, Maha Maglinao, Udo Eichenlaub, et al. (+3)
97 [GO] 2022―Nov―04 Machine Learning Successfully Detects Patients with COVID-19 Prior to PCR Results and Predicts Their Survival Based on Standard Laboratory Parameters in an Observational Study Filip Styrzynski, Damir Zhakparov, Marco Schmid, Damian Roqueiro, Zuzanna Lukasik, Julia Solek, et al. (+5)
98 [GO] 2022―Oct―15 Efficacy of Bacillus Calmette-Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial Sanjeev Sinha, Anuj Ajayababu, Himanshu Thukral, Sushil Gupta, Subhasish Kamal Guha, Ayan Basu, et al. (+21)
99 [GO] 2022―Oct―15 Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial Maria J. G. T. Vehreschild, Petar Atanasov, Kateryna Yurko, Cristian Oancea, Georgi Popov, Valentina Smesnoi, et al. (+6)
100 [GO] 2022―Oct―11 PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the United States Liping Huang, Jennifer L. Nguyen, Tamuno Alfred, Johnna Perdrizet, Alejandro Cane, Adriano Arguedas
101 [GO] 2022―Oct―01 Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19 Jessica J. Jalbert, Mohamed Hussein, Vera Mastey, Robert J. Sanchez, Degang Wang, Dana Murdock, et al. (+6)
102 [GO] 2022―Sep―26 Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the Pandemic Marc Scherlinger, Cédric Lemogne, Renaud Felten, Jean Sibilia
103 [GO] 2022―Sep―24 Performance Evaluation of the Microfluidic Antigen LumiraDx SARS-CoV-2 and Flu A/B Test in Diagnosing COVID-19 and Influenza in Patients with Respiratory Symptoms Jayne E. Ellis, Poppy Guest, Vicki Lawson, Julia Loecherbach, Nigel Lindner, Andrew McCulloch
104 [GO] 2022―Sep―12 COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups Sherrie L. Kelly, Epke A. Le Rutte, Maximilian Richter, Melissa A. Penny, Andrew J. Shattock
105 [GO] 2022―Sep―04 First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults Venkateshan S. Prativadibhayankaram, Lawrence Soon-U Lee, David Lye, Xu Xiaoying, Ranjani Nellore, Vishal Pendharkar, et al. (+18)
106 [GO] 2022―Aug―25 Clinical Utility of Circulating Pneumoproteins as Diagnostic and Prognostic Biomarkers in COVID-19: A Systematic Review and Meta-analysis Yani Ke, Yuqing Zhu, Shuaihang Chen, Jie Hu, Ruilin Chen, Wu Li, Shan Liu
107 [GO] 2022―Aug―01 Herpes Simplex Virus 1 (HSV-1) Reactivation in Critically Ill COVID-19 Patients: A Brief Narrative Review Daniele Roberto Giacobbe, Stefano Di Bella, Antonio Lovecchio, Lorenzo Ball, Andrea De Maria, Antonio Vena, et al. (+5)
108 [GO] 2022―Jun―29 Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic E. Ariza-Vioque, F. Ello, H. Andriamamonjisoa, V. Machault, J. González-Martín, M. C. Calvo-Cortés, et al. (+25)
109 [GO] 2022―May―26 A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia Giovanni Landoni, Lorenzo Piemonti, Antonella d’Arminio Monforte, Paolo Grossi, Alberto Zangrillo, Enrico Bucci, et al. (+7)
110 [GO] 2022―May―25 Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review Norka I. Napuri, Daniel Curcio, David L. Swerdlow, Amit Srivastava
111 [GO] 2022―May―17 Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study Szu-Min Hsieh, Shan-Chwen Chang, Hao-Yuan Cheng, Shin-Ru Shih, Chia En Lien
112 [GO] 2022―May―16 Correction to: Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection Eszter Fodor, Veronika Müller, Zsolt Iványi, Tímea Berki, Olga Kuten Pella, István Hornyák, et al. (+13)
113 [GO] 2022―May―11 Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19 Nicholas Rebold, Sara Alosaimy, Taylor Morrisette, Dana Holger, Abdalhamid M. Lagnf, Iman Ansari, et al. (+9)
114 [GO] 2022―May―09 Combined RT-PCR and Host Response Point-of-Care Testing in Patients Hospitalised with Suspected COVID-19: A Prospective Diagnostic Accuracy Study Nathan J. Brendish, Alex R. Tanner, Stephen Poole, Kate R. Beard, Vasanth V. Naidu, Christopher T. Mansbridge, et al. (+4)
115 [GO] 2022―Apr―27 Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study Rodrigo Alonso, Ana M. Camon, Celia Cardozo, Laia Albiach, Daiana Agüero, M. Angeles Marcos, et al. (+113)
116 [GO] 2022―Apr―26 Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis Shanshan Yang, Shengshu Wang, Mingmei Du, Miao Liu, Yunxi Liu, Yao He
117 [GO] 2022―Apr―21 Interferon Treatments for SARS-CoV-2: Challenges and Opportunities Diya Jhuti, Angeli Rawat, Christina M. Guo, Lindsay A. Wilson, Edward J. Mills, Jamie I. Forrest
118 [GO] 2022―Mar―21 Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan Shinya Tsuzuki, Kayoko Hayakawa, Yohei Doi, Tomohiro Shinozaki, Yukari Uemura, Nobuaki Matsunaga, et al. (+15)
119 [GO] 2022―Mar―10 Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study Lakshmi Swaminathan, Scott Kaatz, Heather Chubb, Kim Tae, Mayur S. Ramesh, Raef Fadel, et al. (+4)
120 [GO] 2022―Feb―18 Efficacy and Safety of a Phytopharmaceutical Drug Derived from Cocculus hirsutus in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial Sadhna Joglekar, Shivakumar S. Iyer, Rohit Parate, Akash A. Khobragade, Rakesh Patil, Shashi Bhushan, et al. (+6)
121 [GO] 2022―Feb―16 Machine Learning-Based COVID-19 Patients Triage Algorithm Using Patient-Generated Health Data from Nationwide Multicenter Database Min Sue Park, Hyeontae Jo, Haeun Lee, Se Young Jung, Hyung Ju Hwang
122 [GO] 2022―Feb―04 Letter to the Editor Regarding “Influence of Baseline Physical Activity as a Modifying Factor on COVID-19 Mortality: A Single-Center, Retrospective Study” Charles Phillipe de Lucena Alves, Marcelo Rodrigues dos Santos, Daisy Motta-Santos
123 [GO] 2022―Feb―02 A Response to: Letter to the Editor Regarding “Influence of Baseline Physical Activity as a Modifying Factor on COVID-19 Mortality: A Single-Center, Retrospective Study” Ricardo Salgado-Aranda
124 [GO] 2022―Feb―02 EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study Ryan D. Kilpatrick, Olga Sánchez-Soliño, Negar Niki Alami, Christopher Johnson, Yixin Fang, Lani R. Wegrzyn, et al. (+4)
125 [GO] 2022―Jan―25 Correction to: Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19 Ritam Das, Komal Kotra, Pulkit Singh, Belinda Loh, Sebastian Leptihn, Urmi Bajpai
126 [GO] 2022―Jan―20 Effect of Tocilizumab Treatment on Patients with Coronavirus Disease 2019 and Bacteremia: A Retrospective Cohort Study Masaatsu Kuwahara, Misa Kamigaito, Shou Nitta, Kana Hasegawa, Hiromoto Murakami, Tomoyuki Kobayashi, et al. (+3)
127 [GO] 2021―Dec―29 Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy Tobias Homan, Francesca Fortunato, Gaetano Corso, Pier Luigi Lopalco, Rosa Prato, Domenico Martinelli
128 [GO] 2021―Dec―27 Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season Gaël Dos Santos, Hao Wang, Pooja Jindal, Maria Rybo, Hélène Roul, Sridevi Pallem, et al. (+8)
129 [GO] 2021―Dec―10 Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) Tommaso Manciulli, Michele Spinicci, Alessandro Bartoloni, Lorenzo Zammarchi
130 [GO] 2021―Dec―10 A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) Matteo Bassetti, Daniele Roberto Giacobbe, Paolo Bruzzi, Emanuela Barisione, Stefano Centanni, Nadia Castaldo, et al. (+22)
131 [GO] 2021―Dec―08 A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2 Qian Zhang, Renpeng Zhou, Jingjing Yang, Changlin Dou, Tianyi Gan, Fujia Liu, et al. (+4)
132 [GO] 2021―Dec―03 Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine Sarinya Boongird, Piyatida Chuengsaman, Chavachol Setthaudom, Arkom Nongnuch, Montira Assanatham, Salinnart Phanprasert, et al. (+6)
133 [GO] 2021―Nov―24 Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection Eszter Fodor, Veronika Müller, Zsolt Iványi, Tímea Berki, Olga Kuten Pella, István Hornyák, et al. (+13)
134 [GO] 2021―Nov―22 Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19 Ritam Das, Komal Kotra, Pulkit Singh, Belinda Loh, Sebastian Leptihn, Urmi Bajpai
135 [GO] 2021―Nov―14 A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection Michael Roshon, Luciano Lemos-Filho, Holli Cherevka, Laura Goldberg, Kristin Salottolo, David Bar-Or
136 [GO] 2021―Nov―11 Lack of Prognostic Value of SARS-CoV2 RT-PCR Cycle Threshold in the Community Miguel J. Martínez, Luca Basile, Antoni Sisó-Almirall, Victor Cristino, Genoveva Cuesta, Juan Carlos Hurtado, et al. (+7)
137 [GO] 2021―Nov―10 Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials Thundon Ngamprasertchai, Rattagan Kajeekul, Chaisith Sivakorn, Narisa Ruenroegnboon, Viravarn Luvira, Tanaya Siripoon, Nantasit Luangasanatip
138 [GO] 2021―Oct―28 Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data Natalia A. Díaz, Rosa de Miguel, Fernando Agüero, Omar Sued, José R. Arribas, Juan Ambrosioni, et al. (+40)
139 [GO] 2021―Oct―25 Epidemiology of Viruses Causing Pediatric Community Acquired Pneumonia in Shanghai During 2010-2020: What Happened Before and After the COVID-19 Outbreak? Fei Li, Yuhan Zhang, Peng Shi, Linfeng Cao, Liyun Su, Yulan Zhang, et al. (+4)
140 [GO] 2021―Oct―23 Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan Tingting Liao, Daquan Meng, Lijuan Xiong, Shuting Wu, Lian Yang, Sufei Wang, et al. (+8)
141 [GO] 2021―Sep―28 In Vitro Evaluation of the Virucidal Activity of Different Povidone-Iodine Formulations Against Murine and Human Coronaviruses Manjunath Shet, Rosa Hong, David Igo, Marc Cataldo, Sailaja Bhaskar
142 [GO] 2021―Sep―16 Antibiotic Prescriptions Targeting Bacterial Respiratory Infections in Admitted Patients with COVID-19: A Prospective Observational Study Johan Van Laethem, Stephanie Wuyts, Sven Van Laere, Silke Dirkx, Lucie Seyler, Rembert Mertens, et al. (+4)
143 [GO] 2021―Sep―02 Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) Matteo Bassetti, Daniele Roberto Giacobbe, Paolo Bruzzi, Emanuela Barisione, Stefano Centanni, Nadia Castaldo, et al. (+50)
144 [GO] 2021―Aug―30 Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program Oscar Salva, Pablo A. Doreski, Celia S. Giler, Dario C. Quinodoz, Lucia G. Guzmán, Sonia E. Muñoz, et al. (+20)
145 [GO] 2021―Aug―27 Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial Masaharu Shinkai, Kenji Tsushima, Shingo Tanaka, Eri Hagiwara, Norihito Tarumoto, Ichiro Kawada, et al. (+33)
146 [GO] 2021―Aug―25 Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern Marco Falcone, Giusy Tiseo, Beatrice Valoriani, Chiara Barbieri, Sara Occhineri, Paola Mazzetti, et al. (+6)
147 [GO] 2021―Aug―25 Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals Soumya Jaganathan, Francis Stieber, Sonia N. Rao, Vladyslav Nikolayevskyy, Davide Manissero, Nadia Allen, et al. (+2)
148 [GO] 2021―Aug―13 Efficacy and Safety of Corticosteroid Use in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis Yuqing Cui, Yali Sun, Junyi Sun, Huoyan Liang, Xianfei Ding, Xueyi Sun, et al. (+2)
149 [GO] 2021―Aug―13 Lower Serum Angiotensin-Converting Enzyme Level in Relation to Hyperinflammation and Impaired Antiviral Immune Response Contributes to Progression of COVID-19 Infection Yuying Chen, Da Huang, Wei Yuan, Jiang Chang, Zhize Yuan, Di Wu, et al. (+4)
150 [GO] 2021―Aug―10 Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial Mohammad Bosaeed, Ebrahim Mahmoud, Ahmad Alharbi, Hadeel Altayib, Hawra Albayat, Faisal Alharbi, et al. (+24)
151 [GO] 2021―Aug―10 Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis-Michael Voutsinas, Periklis Panagopoulos, Maria Kosmidou, et al. (+25)
152 [GO] 2021―Aug―10 Phase II Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure Yuichiro Shindo, Yasuhiro Kondoh, Akiko Kada, Yohei Doi, Keisuke Tomii, Hiroshi Mukae, et al. (+13)
153 [GO] 2021―Aug―10 A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2 Ramesh Nathan, Imad Shawa, Inmaculada De La Torre, Jennifer M. Pustizzi, Natalie Haustrup, Dipak R. Patel, Gregory Huhn
154 [GO] 2021―Aug―09 Multicentre Performance Evaluation of the Elecsys Anti-SARS-CoV-2 Immunoassay as an Aid in Determining Previous Exposure to SARS-CoV-2 Elena Riester, Mario Majchrzak, Annelies Mühlbacher, Caroline Tinguely, Peter Findeisen, Johannes Kolja Hegel, et al. (+6)
155 [GO] 2021―Aug―09 Multicenter Evaluation of a Fully Automated High-Throughput SARS-CoV-2 Antigen Immunoassay Dominik Nörz, Flaminia Olearo, Stojan Perisic, Matthias F. Bauer, Elena Riester, Tanja Schneider, et al. (+3)
156 [GO] 2021―Jul―23 Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series Emanuela Messina, Anna Danise, Giulio Ferrari, Andrea Andolina, Matteo Chiurlo, Marie Razanakolona, et al. (+3)
157 [GO] 2021―Jul―22 Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations Fei Chen, Lanting Hao, Shiheng Zhu, Xinyuan Yang, Wenhao Shi, Kai Zheng, et al. (+2)
158 [GO] 2021―Jul―14 Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital Elisabeth Paramythiotou, George Dimopoulos, Nikolaos Koliakos, Maria Siopi, Sophia Vourli, Spyros Pournaras, Joseph Meletiadis
159 [GO] 2021―Jul―12 COVID-19: Zinc and Angiotensin-Converting Enzyme 2 (ACE2) Deficiencies as Determinants of Risk and Severity of Disease: A Narrative Review Miklos P. Salgo
160 [GO] 2021―Jul―11 Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab’s Place in COVID-19 Pneumonia Timothée Klopfenstein, Vincent Gendrin, Aurélie Gerazime, Thierry Conrozier, Jean-Charles Balblanc, Pierre-Yves Royer, et al. (+9)
161 [GO] 2021―Jul―10 Refining “Long-COVID” by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection Marc Scherlinger, Renaud Felten, Floriane Gallais, Charlotte Nazon, Emmanuel Chatelus, Luc Pijnenburg, et al. (+14)
162 [GO] 2021―Jul―09 Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis Weijun Jiang, Weiwei Li, Qiuyue Wu, Ying Han, Jing Zhang, Tao Luo, et al. (+4)
163 [GO] 2021―Jun―21 Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 Elda Righi, Massimo Mirandola, Fulvia Mazzaferri, Elisa Razzaboni, Amina Zaffagnini, Anna Erbogasto, et al. (+12)
164 [GO] 2021―Jun―16 The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece Evangelos J. Giamarellos-Bourboulis, George L. Daikos, Panagiotis Gargalianos, Charalambos Gogos, Marios Lazanas, Periklis Panagopoulos, et al. (+3)
165 [GO] 2021―Jun―16 In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients Raquel Rubio-Acero, Noemi Castelletti, Volker Fingerle, Laura Olbrich, Abhishek Bakuli, Roman Wölfel, et al. (+130)
166 [GO] 2021―Jun―14 A Novel Prediction Model of COVID-19 Progression: A Retrospective Cohort Study Wei Xu, ChenLu Huang, Ling Fei, WeiXia Li, XuDong Xie, Qiang Li, Liang Chen
167 [GO] 2021―Jun―13 Reduction in Sporadic Norovirus Infections Following the Start of the COVID-19 Pandemic, 2019-2020, Philadelphia Irving Nachamkin, Melissa Richard-Greenblatt, Mei Yu, Hong Bui
168 [GO] 2021―Jun―11 Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19 Fernanda Meira, Estela Moreno-García, Laura Linares, Irene Macaya, Adria Tomé, Marta Hernández-Meneses, et al. (+17)
169 [GO] 2021―Jun―10 Dynamic Changes in the Immune Response Correlate with Disease Severity and Outcomes During Infection with SARS-CoV-2 Fang Zheng, Ruochan Chen, Run Yao, Yaxiong Huang, Xin Tan, Jiyang Liu, et al. (+2)
170 [GO] 2021―May―29 Dynamic Antibody Responses in Patients with Different Severity of COVID-19: A Retrospective Study Wanrong Lu, Ping Wu, Liang He, Yifan Meng, Peng Wu, Wencheng Ding, Jia Liu
171 [GO] 2021―May―11 Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia Matthew Geriak, Fadi Haddad, Ravina Kullar, Kristina L. Greenwood, MacKenzie Habib, Cole Habib, et al. (+2)
172 [GO] 2021―May―03 Prevalence and Mortality due to COVID-19 in HIV Co-Infected Population: A Systematic Review and Meta-Analysis Min Liang, Ning Luo, Mafeng Chen, Chunna Chen, Shivank Singh, Shantanu Singh, Shifan Tan
173 [GO] 2021―Apr―29 A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Belén Ruiz-Antorán, Aránzazu Sancho-López, Ferrán Torres, Ana Fernández-Cruz
174 [GO] 2021―Apr―29 Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study Rajesh Naidu Janapala, Jigar Patel, Omar Belfaqeeh, Abdulla Alhashmi, Ali Pourmand
175 [GO] 2021―Apr―07 Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019 Alanna C. McEneny-King, Jonathan P. R. Monteleone, Shamsah D. Kazani, Stephan R. Ortiz
176 [GO] 2021―Mar―31 A Novel Prediction Model for Long-Term SARS-CoV-2 RNA Shedding in Non-Severe Adult Hospitalized Patients with COVID-19: A Retrospective Cohort Study Chen Lu Huang, Ling Fei, WeiXia Li, Wei Xu, Xu Dong Xie, Qiang Li, Liang Chen
177 [GO] 2021―Mar―22 A Survey of Provider-Reported Use and Perceived Effectiveness of Medications for Symptom Management in Telemedicine and Outpatient Visits for Mild COVID-19 James B. O’Keefe, Lydia C. Newsom, Thomas H. Taylor
178 [GO] 2021―Mar―18 Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach Hsiao-Hsuan Jen, Wei-Jung Chang, Ting-Yu Lin, Chen-Yang Hsu, Amy Ming-Fang Yen, Chao-Chih Lai, Tony Hsiu-Hsi Chen
179 [GO] 2021―Mar―14 Influence of Baseline Physical Activity as a Modifying Factor on COVID-19 Mortality: A Single-Center, Retrospective Study Ricardo Salgado-Aranda, Nicasio Pérez-Castellano, Ivan Núñez-Gil, A. Josué Orozco, Norberto Torres-Esquivel, Jesús Flores-Soler, et al. (+9)
180 [GO] 2021―Feb―24 A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study Paul K. Drain, Madhavi Ampajwala, Christopher Chappel, Andre B. Gvozden, Melanie Hoppers, Melody Wang, et al. (+4)
181 [GO] 2021―Feb―02 Computational and Experimental Studies Reveal That Thymoquinone Blocks the Entry of Coronaviruses Into In Vitro Cells Huan Xu, Bing Liu, Zhen Xiao, Meiling Zhou, Lin Ge, Fan Jia, et al. (+8)
182 [GO] 2021―Jan―25 COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options Nicholas Rebold, Dana Holger, Sara Alosaimy, Taylor Morrisette, Michael Rybak
183 [GO] 2021―Jan―23 The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort Abdulkarim Abdulrahman, Islam AlSayed, Marwa AlMadhi, Jumana AlArayed, Sara Jaafar Mohammed, Aesha Khalid Sharif, et al. (+3)
184 [GO] 2021―Jan―22 Clinical Characteristics of Patients with Severe and Critical COVID-19 in Wuhan: A Single-Center, Retrospective Study Zhaohui Chen, Junyi Hu, Lilong Liu, Youpeng Zhang, Dandan Liu, Ming Xiong, et al. (+3)
185 [GO] 2021―Jan―12 Clinical Diagnostic Study of a Novel Injection Molded Swab for SARS-Cov-2 Testing Joshua K. Tay, Gail B. Cross, Louisa Sun, Alfred Chia, Jeremy Chee, Jerold Loh, et al. (+15)
186 [GO] 2021―Jan―09 Filling the Gap Until Full Vaccine Deployment in the War on Coronavirus Disease-19 Sabrina Mattoli
187 [GO] 2021―Jan―08 Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study Antonio Vena, Lucia Taramasso, Antonio Di Biagio, Malgorzata Mikulska, Chiara Dentone, Andrea De Maria, et al. (+18)
188 [GO] 2020―Dec―06 Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study Belén Ruiz-Antorán, Aránzazu Sancho-López, Ferrán Torres, Víctor Moreno-Torres, Itziar de Pablo-López, Paulina García-López, et al. (+18)
189 [GO] 2020―Nov―26 Correction to: Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains Eriko Padron-Regalado
190 [GO] 2020―Nov―09 Correction to: Early Treatment of COVID-19 Disease: A Missed Opportunity Jamie I. Forrest, Craig R. Rayner, Jay J. H. Park, Edward J. Mills
191 [GO] 2020―Nov―02 Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study Laila Carolina Abu Esba, Rahaf Ali Alqahtani, Abin Thomas, Nour Shamas, Lolowa Alswaidan, Gahdah Mardawi
192 [GO] 2020―Oct―28 Multidimensional Analysis of Risk Factors for the Severity and Mortality of Patients with COVID-19 and Diabetes Juan Huang, Lin Zhu, Xiangli Bai, Xiong Jia, Yajing Lu, Aiping Deng, et al. (+2)
193 [GO] 2020―Oct―16 Chest CT Features of 182 Patients with Mild Coronavirus Disease 2019 (COVID-19) Pneumonia: A Longitudinal, Retrospective and Descriptive Study Huaping Liu, Shiyong Luo, Youming Zhang, Yuzhu Jiang, Yuting Jiang, Yayi Wang, et al. (+6)
194 [GO] 2020―Oct―13 Early Treatment of COVID-19 Disease: A Missed Opportunity Jamie I. Forrest, Craig R. Rayner, Jay J. H. Park, Edward J. Mills
195 [GO] 2020―Sep―28 Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study Cheng Ding, Xuewen Feng, Yanfei Chen, Jing Yuan, Ping Yi, Yongtao Li, et al. (+6)
196 [GO] 2020―Sep―20 Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial Danyal Ibrahim, Latha Dulipsingh, Lisa Zapatka, Reginald Eadie, Rebecca Crowell, Kendra Williams, et al. (+4)
197 [GO] 2020―Sep―16 Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All Grant W. Waterer, Jordi Rello
198 [GO] 2020―Sep―04 Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals Georg M. N. Behrens, Anne Cossmann, Metodi V. Stankov, Bianca Schulte, Hendrik Streeck, Reinhold Förster, et al. (+16)
199 [GO] 2020―Sep―02 Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study Qiang Li, Weixia Li, Yinpeng Jin, Wei Xu, Chenlu Huang, Li Li, et al. (+3)
200 [GO] 2020―Aug―18 Correction to: A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19 Sonia N. Rao, Davide Manissero, Victoria R. Steele, Josep Pareja
201 [GO] 2020―Aug―12 Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19 Joseph Meletiadis, Sotirios Tsiodras, Panagiotis Tsirigotis
202 [GO] 2020―Aug―01 The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse Taylor Morrisette, Thomas P. Lodise, Marc H. Scheetz, Srijib Goswami, Jason M. Pogue, Michael J. Rybak
203 [GO] 2020―Jul―28 A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19 Sonia N. Rao, Davide Manissero, Victoria R. Steele, Josep Pareja
204 [GO] 2020―Jul―10 That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19 Matthew R. Davis, Erin K. McCreary, Jason M. Pogue
205 [GO] 2020―Jul―08 Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease Danielle E. Anderson, Velraj Sivalingam, Adrian Eng Zheng Kang, Abhishek Ananthanarayanan, Harsha Arumugam, Timothy M. Jenkins, et al. (+2)
206 [GO] 2020―May―30 COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia Helvécio Cardoso Corrêa Póvoa, Gabriela Ceccon Chianca, Natalia Lopes Pontes Póvoa Iorio
207 [GO] 2020―May―27 Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review David C. Fajgenbaum, Johnson S. Khor, Alexander Gorzewski, Mark-Avery Tamakloe, Victoria Powers, Joseph J. Kakkis, et al. (+16)
208 [GO] 2020―Apr―23 Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains Eriko Padron-Regalado
209 [GO] 2020―Apr―08 Coronavirus: Update Related to the Current Outbreak of COVID-19 Giovanni Gabutti, Erica d’Anchera, Federica Sandri, Marta Savio, Armando Stefanati
 [1] 

209 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.006 sec